Richmond News Now

Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)

 Breaking News
  • No posts were found

Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)

October 12
19:20 2021
Chronic Obstructive Pulmonary Disease market shows moderate growth in the 7MM during the study period (2018-30)
Chronic Obstructive Pulmonary Disease Market
Increased understanding of the distinct histology has enabled the development of COPD-specific drugs and has begun to reveal the parallels and differences between the two.

DelveInsight’s Chronic Obstructive Pulmonary Disease market report provides a thorough comprehension of the Chronic Obstructive Pulmonary Disease historical and forecasted epidemiology and the Chronic Obstructive Pulmonary Disease market trends in the 7MM. The Chronic Obstructive Pulmonary Disease report also analyzes the current Chronic Obstructive Pulmonary Disease treatment algorithms, Chronic Obstructive Pulmonary Disease market dynamics, and unmet medical needs.

Key Takeaways from the Chronic Obstructive Pulmonary Disease Market Report

  • As per DelveInsight estimates, Chronic Obstructive Pulmonary Disease diagnosed prevalence was over 31 million in the 7MM in 2020, with the US accounting for maximum COPD diagnosed prevalence.

  • Among the EU5 countries, Germany has the highest COPD diagnosed prevalence while Spain had the lowest in 2020.

  • According to DelveInsight COPD epidemiology analysis, females are more likely to be affected than males

  • Several companies such as Sanofi, Regeneron Pharmaceuticals, Verona Pharma PLC, Chiesi Farmaceutici S.p.A., AstraZeneca, GlaxoSmithKline, Mereo BioPharma, and others are developing novel therapies to treat COPD.

  • Key COPD therapies in the pipeline include Itepekimab, Ensifentrine, Dupixent, CHF6001/Tanimilast, Fasenra, Nucala, Acumapimod, and others.

  • The growing prevalence of COPD patients in the 7MM has resulted in a growth in COPD market size.

  • The COPD market size was found to be USD 12,134 million in the 7MM in 2020, which DelveInsight estimates is expected to grow significantly by 2030.

Request for the sample to know more @ Chronic Obstructive Pulmonary Disease Market Research

Chronic Obstructive Pulmonary Disease: Overview

Chronic Obstructive Pulmonary Disease is a prevalent, preventable, and treatable condition defined by chronic respiratory symptoms and airflow limitation caused by airway and alveolar abnormalities, which are mainly induced by considerable exposure to noxious particles or gases.

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation

The Chronic Obstructive Pulmonary Disease report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases

  • Chronic Obstructive Pulmonary Disease Gender-Specific Diagnosed Prevalent Cases

  • Chronic Obstructive Pulmonary Disease Age-Specific Diagnosed Prevalent Cases

  • Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases based on Severity of Airflow

  • Chronic Obstructive Pulmonary Disease Diagnosed Prevalent Cases based on Symptoms and Exacerbation History COPD

Chronic Obstructive Pulmonary Disease Therapeutics Market

COPD treatment focuses on symptom relief, such as coughing and breathing difficulties and preventing respiratory infections. The stage of COPD frequently determines treatments. COPD prevention necessitates some lifestyle adjustments. Smoking cessation is an essential component of any COPD treatment plan. Maintenance and reliever medications are used to treat COPD. The maintenance drugs include inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), fixed-dose combinations of ICS + LABA, tiotropium (TIO), and inhaled ipratropium or fixed-dose combinations of ipratropium + albuterol. Whereas Reliever medications included short-acting beta-agonist (SABA), oral corticosteroid (OCS), nebulized ipratropium or combination ipratropium–albuterol, and antibiotics. 

Chronic Obstructive Pulmonary Disease Market Outlook

Increased awareness of the unique histology has allowed for the development of COPD-specific drugs and has begun to reveal the parallels and distinctions between the two. These factors, along with the anticipated introduction of new therapies such as Itepekimab, Ensifentrine, Dupixent, and others, are expected to drive the COPD market during the forecast period (2021–2030).

Chronic Obstructive Pulmonary Disease Pipeline Therapies and Key Companies

  • Itepekimab: Sanofi/Regeneron Pharmaceuticals

  • Ensifentrine: Verona Pharma PLC

  • Dupixent: Regeneron Pharmaceuticals/Sanofi

  • CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.

  • Fasenra: AstraZeneca

  • Nucala: GlaxoSmithKline

  • Acumapimod: Mereo BioPharma

Get more details on the emerging drugs and companies @ Chronic Obstructive Pulmonary Disease Pipeline Therapies 

Chronic Obstructive Pulmonary Disease Market Drivers

  • Increasing COPD Awareness

  • Emergence in development of emerging therapies 

  • Personalized treatments 

  • Improvement in diagnostic techniques

Chronic Obstructive Pulmonary Disease Market Barriers

  • Late recognition of COPD

  • High cost of treatment

  • Challenges in existing therapies

  • Patient-related barriers

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

COPD Key Companies: Sanofi, Regeneron Pharmaceuticals, Verona Pharma PLC, Chiesi Farmaceutici S.p.A., AstraZeneca, GlaxoSmithKline, Mereo BioPharma, among others. 

COPD Key Pipeline Therapies: Itepekimab, Ensifentrine, Dupixent, CHF6001/Tanimilast, Fasenra, Nucala, Acumapimod, and others.

COPD Market Segmentation: By Geography, By COPD therapies

Analysis: Comparative and conjoint analysis of COPD emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Chronic Obstructive Pulmonary Disease Market Overview at a Glance

4.

Executive Summary of Chronic Obstructive Pulmonary Disease

5.

Key Events

6.

COPD Disease Background and Overview

7.

COPD Epidemiology and Patient Population

8.

Patient Journey

9.

Organizations contributing towards Chronic Obstructive Pulmonary Disease

10.

COPD Key Marketed Therapies

11.

COPD Emerging Drugs

12.

COPD: Potential of Emerging and Current therapies

13.

Chronic Obstructive Pulmonary Disease: Seven Major Market Analysis

14.

KOL Views

15.

COPD Market Drivers

16.

COPD Market Barriers

17.

SWOT Analysis

18.

COPD Unmet Needs

19.

COPD Reimbursement and Market Access

20.

Appendix

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Chronic Pulmonary Infections Market

DelveInsight’s “Chronic Pulmonary Infections – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Pulmonary Infections, historical and forecasted epidemiology, as well as the Chronic Pulmonary Infections market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/